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Abstract
Little is known about CD4+ T-cell immunity to the severe acute respiratory syndrome (SARS) coronavirus. In two SARS patients, we
examined the memory CD4+ T-cell responses to peptides derived from SARS coronavirus structural proteins. We generated CD4+ T-cell lines to 3
peptides from the spike (S) protein and defined their HLA restriction. In one patient, the predominant memory CD4+ T-cell response was directed
against an epitope outside the S protein receptor-binding domain. In both patients, the frequency of CD4+ memory T-cells to virus structural
proteins and anti-SARS coronavirus IgG levels were low by 12 months after infection. This report expands our understanding of the specificity
and duration of anti-SARS coronavirus CD4+ T-cell immune responses.
© 2007 Elsevier Inc. All rights reserved.Keywords: SARS; Coronavirus; CD4+ T-cell; ImmunityThe severe acute respiratory syndrome (SARS) is caused by
the SARS coronavirus (SARS CoV), and emerged from a
zoonotic origin in late 2002 in southern China (Drosten et al.,
2003). Human-to-human transmission spread SARS to 29
countries. The epidemic ended in July 2003 and produced
8098 cases with an overall 9.6% case-fatality rate (2006). Re-
emergence of SARS CoV transmission in humans is not likely
but remains possible. The potential for other zoonotic corona-
viruses to jump to humans and cause serious illness also exists.
Ideally, vaccine candidates for SARS or SARS-like corona-
viruses should induce robust humoral and cell-mediated immune
responses. Neutralizing antibodies to SARS CoV are directed
against epitopes in the virus spike (S) structural protein, and
these antibodies elicit protective immunity in animal models of
SARS (Greenough et al., 2005; Roberts et al., 2006; Subbarao et
al., 2004). Less is known about T-cell immunity to SARS CoV
infection, particularly CD4+ T-helper immunity that could
promote protective antibody development.⁎ Corresponding author. Fax: +1 508 856 4890.
E-mail address: daniel.libraty@umassmed.edu (D.H. Libraty).
0042-6822/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2007.07.015We undertook a study to characterize T-cell responses
directed against the structural proteins of SARS CoV from two
healthcare workers who recovered from SARS. Our approach
was to first identify peptides that stimulated interferon (IFN)-γ
responses from memory T-cells in as unbiased a fashion as
possible. We generated and characterized CD4+ T-cell lines to 3
peptides, and measured the circulating frequencies of peptide-
specific memory T-cells 6–30 months after infection.
Results and discussion
Peptide pool screening of peripheral blood mononuclear cells
by IFN-γ ELISPOT
Peripheral blood mononuclear cells (PBMCs) collected
6 months after SARS CoV infection were stimulated in IFN-γ
ELISPOT assays with overlapping peptide pools spanning the
SARS CoV structural proteins (envelope (E), matrix (M),
nucleocapsid (N), and S proteins) (11–12 peptides/pool, peptide
concentration=4 μg/ml). In the PBMC from one recovered
SARS patient (SARS patient #1 – HLA-DR03+08+), there were
17 peptide pools that produced ≥25 IFN-γ spot-forming cells
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PBMC from the other recovered SARS patient (SARS patient
#2 – HLA-DR15+), there were no peptide pools that produced
≥25 IFN-γ SFC/106 PBMC even though the response to
phytohemagglutinin was robust. We further stimulated and
expanded SARS patient #2 PBMC in vitro with a pool of
eight peptides that contained predicted high affinity HLA-
DRB1⁎1501 epitopes (S1–18, S307–322, S313–329,M14–31,M22–38,
M90–106, E9–26, E17–34) (Singh and Raghava, 2001; Rammensee
et al., 1999). Memory CD4+ T-cells directed against this peptide
pool were detected by IFN-γ intracellular cytokine staining
(ICS), but only after two rounds of in vitro re-stimulation and
expansion (individual peptide concentration=10 μg/ml) (%
IFN-γ-producing CD3+CD4+ T-cells: SARS patient #2 – 2.6%,
HLA-DR15+ SARS seronegative control – 0.06%).
Since SARS patient #1 had measurable memory CD4+ T-cell
responses ex vivo, we stimulated patient #1 PBMC with 40
different individual peptides taken from the 17 positive pools in
an IFN-γ ELISPOT assay (peptide concentrations=10 μg/ml).
We selected the five peptides with the highest IFN-γ SFC
frequencies (range 14–21/106 PBMC) for further study. These
five peptides were all from the viral S protein.
Generation of T-cell lines
The five S protein-derived peptides were pooled and used for
bulk culture stimulation of convalescent PBMC from SARS
patient #1. 6 T-cell lines directed against 3 peptides (S729–745,
S358–374, S427–444) were successfully established (Table 1). Four
CD4+ T-cell lines recognized peptide S729–745 (TECANLLL-
QYGSFCTQL). 3 of these 4 lines were clearly HLA-DR-
restricted, and CTL activity against allogeneic target cells
suggested HLA-DR08 restriction. The optimal epitope for
HLA-DR08 restricted CD4+ T-cell activation was essentially
the entire 17mer peptide. By IFN-γ ICS (10 μg/ml pep-Table 1
Characteristics of T-cell lines generated from convalescent PBMC of SARS patient
Cell line Peptide specificity % CD4+ a CD3+CD4+
IFN-γ+ cells
C4 S729–745 (TECANLLLQYGSFCTQL) 98% Yes
F2 S729–745 96% n.d.
G7 S729–745 98% Yes
F7 S729–745 97% Yes
F5 S358–374 (STFFSTFKCYGVSATKL) 98% Yes
B4 S427–444 (NIDATSTGNYNYKYRYLR) 85% n.d.
a Cell lines were surface-stained with APC-Cy7.7-conjugated anti-CD3, Alexa
antibodies (mAbs) and analyzed on a FACSAria™ flow cytometer (BD Biosciences
b Cell lines were stimulated with the specified peptide in an IFN-γ ICS assay; resu
c HLA restriction was determined by inhibition of cytotoxic activity in standard 51
compared to isotype control mAbs; n.d.=not done.
d Standard 51Cr release cytotoxic T lymphocyte (CTL) assays were performed using
values are [% lysis of peptide-loaded B-LCLs−% lysis of B-LCLs alone] (mean of t
separate experiments using 2 different allogeneic donor cell lines.tide×6 h), only peptide S729–745, and not the flanking
overlapping peptides S723–738 or S736–753, stimulated IFN-γ
production from the four CD4+ T-cell lines noted above (Fig.
1). The highest HLA-DR08 gene frequencies have been
reported in Latino American and Asian American racial groups,
and HLA-DR08 alleles have been reported at moderate
frequencies in Filipino populations (Mack et al., 2000). Peptide
S358–374 (STFFSTFKCYGVSATKL) also appeared to be HLA-
DR08 restricted. The HLA restriction of peptide S427–444
(NIDATSTGNYNYKYRYLR) was unable to be determined
(Table 1). Neutralizing antibodies to the SARS CoV recognize
epitopes in the receptor-binding domain (RBD) of the S
protein – between amino acids 318 and 510 (He et al., 2005;
Hwang et al., 2006; Li et al., 2005). Two of the three S protein
CD4+ T-cell epitopes we identified are in the RBD (S358–374 and
S427–444). However, the predominant CD4
+ T-cell response in
recovered SARS patient #1 was directed against an epitope
outside the RBD (S729–745).
Frequencies of SARS CoV peptide-specific memory CD4+
T-cells
The frequency of IFN-γ+ SFC to peptide S729–745 was
greatest 6 months after SARS CoV infection in patient #1, and
decreased to near the limit of detection by IFN-γ ELISPOT
12 months onward (≤5/106 PBMC) (Fig. 2a). S729–745-specific
CTL activity could still be detected after in vitro re-stimulation
of SARS patient #1 PBMC collected at 12 months (7.6%
S729–745-specific lysis), but not at 24 and 30 months. The
waning of S729–745-specific memory T-cells paralleled the
waning of anti-SARS CoV IgG levels in SARS patient #1. Anti-
SARS CoV IgG levels were already 4-fold lower in patient #2
than patient #1 at 6 months (Fig. 2b). Anti-SARS CoV IgG and
memory CD4+ T-cell responses were weaker or waned more
rapidly in patient #2 compared to patient #1.#1
b











HLA-DR 57% 3% 52%
HLA-DR 66% −1% 32%
HLA-DR 54% 3% 14%
Not blocked by
mAbs to HLA-DR,
-DP, -DQ, or -ABC
72% −2% 29%
HLA-DR 31% 0% 14%
n.d. 35% 0% 2%
405-conjugated anti-CD4, and APC-Cy5.5-conjugated anti-CD8 monoclonal
, San Jose, CA); values are % of CD3+ lymphocytes that were also CD4+.
lts are whether the IFN-γ+ cells in the cell line were CD3+CD4+; n.d.=not done.
Cr release CTL assays in the presence of blocking mAbs to the HLA haplotype
autologous and allogeneic B-lymphoblastoid cell lines (B-LCLs) as target cells;
riplicates); results using allogeneic B-LCL targets are representative of at least 2
Fig. 1. Peptide S729–745 from the SARS CoV spike (S) protein contains a CD4
+ T-cell epitope. (a) The G7 cell line (Table 1) was surface-stained with APC-Cy7-
conjugated anti-CD3, Alexa405-conjugated anti-CD4, and APC-Cy5.5-conjugated anti-CD8 mAbs and gated on CD3+ lymphocytes. (b) The G7 cell line was
stimulated with peptide S723–738 (YICGDSTECANLLLQY), peptide S729–745 (TECANLLLQYGSFCTQL), or peptide S736–753 (LQYGSFCTQLNRALSGIA)
(10 μg/ml×6 h) in an IFN-γ ICS assay. Cells were gated on CD3+CD14/19/56−CD8− lymphocytes. Results are representative of the findings in the other S729–745-
specific T-cell lines.
319D.H. Libraty et al. / Virology 368 (2007) 317–321The S729–745-specific memory CD4
+ T-cell frequency in
SARS patient #1 measured by IFN-γ ELISPOT and ICS was
0.003–0.004%. It was notably higher than in SARS patient #2
(HLA-DR15+) and 7 seronegative close contacts including 2
that were HLA-DR08+ (Fig. 2c). An epitope-specific CD4+ T-
cell frequency of 0.003–0.004% 6 months after infection is
approximately 10-fold lower than what has been reported
1 month after natural influenza virus infection in adults
(Linnemann et al., 2000). While influenza and SARS are both
respiratory virus infections, the CD4+ T-cell response to
influenza in adults is a secondary one, compared to a primary
CD4+ T-cell response for SARS.
Even though we generated CD4+ T-cell lines to peptides
S358–374 and S427–444 from patient #1 PBMC, the direct ex vivo
circulating frequencies of memory T-cells to these peptides were
low and near the limit of detection by IFN-γ ELISPOT 6–
30 months after infection (≤8/106 PBMC). The low S358–374 and
S427–444-specific memory T-cell frequencies in SARS patient #1
were not different than in SARS patient #2 or 7 seronegative close
contacts (Fig. 2c). CD4+ T-cell responses to peptides S358–374 and
S427–444 were weaker or decreased more rapidly than the CD4
+ T-
cell response to S729–745 in SARS patient #1. CD4
+ T-cell
responses to any SARS CoV structural protein epitopes were
weaker or decreased more rapidly in SARS patient #2 compared
to patient #1. However, our results cannot determine what levels
of peptide-specific CD4+ memory T-cells or anti-SARS CoV IgG
are associated with effective SARS CoV immunity.One other group has measured SARS CoV-specific CD4+
memory T-cell responses in recovered SARS individuals (Peng
et al., 2006a,b; Yang et al., 2006). Individual CD4+ T-cell
epitopes were identified within the N protein (Peng et al.,
2006b). We believe our study is the first to identify individual
human CD4+ T-cell epitopes within the SARS CoV S protein
and characterize their HLA restriction (HLA-DR08). We have
also identified potential HLA-DR15-restricted peptides from
the SARS CoV S, M, and E proteins. Some have suggested that
the SARS CoV S protein RBD by itself could be an effective
subunit vaccine (He et al., 2005). Our findings suggest that
dominant SARS CoV anti-S CD4+ T-helper responses could be
directed to epitopes outside the RBD. Our data also illustrate
that in some individuals humoral and CD4+ T-cell immunity to
SARS CoV may wane rapidly. What levels of humoral or CD4+
T-cell immunity are associated with clinical protection remain
unknown. An improved understanding of SARS CoV-specific
memory immune responses will help guide future vaccination
strategies in the event of SARS or SARS-like coronavirus re-
emergence in humans.
Materials and methods
Subjects and source of cells
A limited outbreak of SARS occurred in the Philippines in
April 2003 (2003). We collected serial convalescent blood
Fig. 2. Peptide-specific T-cell frequencies and anti-SARS CoV IgG titers in recovered SARS patients. (a) Serial convalescent PBMC collected from SARS patient #1
were stimulated with peptides S729–745, S358–374, and S427–444 in an IFN-γ ELISPOT assay (peptide concentration=10 μg/ml). Results are expressed as number of
peptide-specific IFN-γ spot-forming cells (SFC)/106 PBMC (media background subtracted, mean of triplicate values). (b) Anti-SARS CoV IgG titers were measured
by ELISA to inactivated virus-infected cell lysates in serial plasma samples collected from SARS patients #1 and #2. Fourfold serial dilutions of each plasma sample
were assayed in duplicate. Reciprocal titer b100 was undetectable (coded as reciprocal titer=50). (c) PBMC collected 6 months after the SARS outbreak from the two
SARS patients and 7 SARS seronegative healthy contacts were stimulated with peptides S729–745, S358–374, and S427–444 in an IFN-γ ELISPOT assay (peptide
concentration=10 μg/ml). Two healthy contacts were HLA-DR08+. Results are expressed as number of peptide-specific IFN-γ SFC/106 PBMC (media background
subtracted, mean of triplicate values).
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the outbreak and recovered, and from 16 healthy contacts.
Peripheral blood mononuclear cells (PBMC) and plasma were
aliquoted and cryopreserved. Red blood cell (RBC) pellets
containing granulocytes were used for HLA typing (Biotest
ABDR SSP kit, Biotest Diagnostics Corp., Denville, NJ). All
participants provided written informed consent, and the protocol
was approved by the Institutional Review Boards of the
University of Massachusetts Medical School and the Research
Institute for Tropical Medicine.
Reagents
A total of 266 peptides spanning the SARS CoV envelope,
matrix, nucleocapsid, and spike proteins were provided by NIH/
NIAID BEIResources Repository (Cat# 9900–9903). Thepeptides were 15–17 amino acids in length, overlapping by 10
amino acids.
Assays
IFN-γ ELISPOT assays were performed as previously
described, without addition of co-stimulatory antibodies or
interleukin-2 (Jameson et al., 1998). T-cell lines were established
by bulk culture peptide stimulation, limiting dilution, and
standard 51Cr release CTL assays (Jameson et al., 1998). IFN-γ
ICS assays were performed after 6-h stimulation with peptide in
the presence of a Golgi inhibitor (brefeldin A), as previously
described (Mangada et al., 2004). Anti-SARS CoV IgG titers
were measured by ELISA to inactivated virus-infected cell
lysates in serial plasma samples, as previously described
(Ksiazek et al., 2003). Fourfold serial dilutions of each plasma
321D.H. Libraty et al. / Virology 368 (2007) 317–321sample were assayed in duplicate. A reciprocal titer b100 was
undetectable (coded as reciprocal titer=50). All 16 healthy
contacts had undetectable anti-SARSCoV IgG levels (reciprocal
titer b100).
Acknowledgments
This work was supported by the National Institutes of Health
grants R21 AI060791 and U19 AI57319. The contents of this
publication are solely the responsibility of the authors and do
not necessarily represent the official views of the National
Institutes of Health.
The authors would like to thank Pam Pazoles for performing
the HLA genotyping, and the staff at the RITM Hospital for
facilitating the blood collections.
References
(2003). SARS outbreak in the Philippines. Wkly. Epidemiol. Rec. 78 (22),
189–92.
(2006). “SARS: how a global epidemic was stopped.” World Health
Organization, Western Pacific Region. WHO Press, Geneva Switzerland.
Drosten, C., Gunther, S., Preiser, W., van der Werf, S., Brodt, H.R., Becker, S.,
Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R.A., Berger, A.,
Burguiere, A.M., Cinatl, J., Eickmann, M., Escriou, N., Grywna, K.,
Kramme, S., Manuguerra, J.C., Muller, S., Rickerts, V., Sturmer, M., Vieth,
S., Klenk, H.D., Osterhaus, A.D., Schmitz, H., Doerr, H.W., 2003.
Identification of a novel coronavirus in patients with severe acute respiratory
syndrome. N. Engl. J. Med. 348 (20), 1967–1976.
Greenough, T.C., Babcock, G.J., Roberts, A., Hernandez, H.J., Thomas Jr.,W.D.,
Coccia, J.A., Graziano, R.F., Srinivasan, M., Lowy, I., Finberg, R.W.,
Subbarao, K., Vogel, L., Somasundaran, M., Luzuriaga, K., Sullivan, J.L.,
Ambrosino, D.M., 2005. Development and characterization of a severe acute
respiratory syndrome-associated coronavirus-neutralizing human monoclo-
nal antibody that provides effective immunoprophylaxis in mice. J. Infect.
Dis. 191 (4), 507–514.
He, Y., Lu, H., Siddiqui, P., Zhou, Y., Jiang, S., 2005. Receptor-binding domain
of severe acute respiratory syndrome coronavirus spike protein contains
multiple conformation-dependent epitopes that induce highly potent
neutralizing antibodies. J. Immunol. 174 (8), 4908–4915.
Hwang, W.C., Lin, Y., Santelli, E., Sui, J., Jaroszewski, L., Stec, B., Farzan, M.,
Marasco, W.A., Liddington, R.C., 2006. Structural basis of neutralization by
a human anti-severe acute respiratory syndrome spike protein antibody, 80R.
J. Biol. Chem. 281 (45), 34610–34616.
Jameson, J., Cruz, J., Ennis, F.A., 1998. Human cytotoxic T-lymphocyte
repertoire to influenza A viruses. J. Virol. 72 (11), 8682–8689.Ksiazek, T.G., Erdman, D., Goldsmith, C.S., Zaki, S.R., Peret, T., Emery, S.,
Tong, S., Urbani, C., Comer, J.A., Lim, W., Rollin, P.E., Dowell, S.F.,
Ling, A.E., Humphrey, C.D., Shieh, W.J., Guarner, J., Paddock, C.D.,
Rota, P., Fields, B., DeRisi, J., Yang, J.Y., Cox, N., Hughes, J.M., LeDuc,
J.W., Bellini, W.J., Anderson, L.J., 2003. A novel coronavirus associated
with severe acute respiratory syndrome. N. Engl. J. Med. 348 (20),
1953–1966.
Li, F., Li, W., Farzan, M., Harrison, S.C., 2005. Structure of SARS coronavirus
spike receptor-binding domain complexed with receptor. Science 309
(5742), 1864–1868.
Linnemann, T., Jung, G., Walden, P., 2000. Detection and quantification of CD4
(+) T cells with specificity for a new major histocompatibility complex class
II-restricted influenza A virus matrix protein epitope in peripheral blood of
influenza patients. J. Virol. 74 (18), 8740–8743.
Mack, S.J., Bugawan, T.L., Moonsamy, P.V., Erlich, J.A., Trachtenberg, E.A.,
Paik, Y.K., Begovich, A.B., Saha, N., Beck, H.P., Stoneking, M.,
Erlich, H.A., 2000. Evolution of Pacific/Asian populations inferred from
HLA class II allele frequency distributions. Tissue Antigens 55 (5),
383–400.
Mangada, M.M., Ennis, F.A., Rothman, A.L., 2004. Quantitation of dengue
virus specific CD4+ T cells by intracellular cytokine staining. J. Immunol.
Methods 284 (1–2), 89–97.
Peng, H., Yang, L.T., Li, J., Lu, Z.Q., Wang, L.Y., Koup, R.A., Bailer, R.T., Wu,
C.Y., 2006a. Human memory T cell responses to SARS-CoV E protein.
Microbes Infect. 8 (9–10), 2424–2431.
Peng, H., Yang, L.T., Wang, L.Y., Li, J., Huang, J., Lu, Z.Q., Koup, R.A., Bailer,
R.T., Wu, C.Y., 2006b. Long-lived memory T lymphocyte responses against
SARS coronavirus nucleocapsid protein in SARS-recovered patients.
Virology 351 (2), 466–475.
Rammensee, H., Bachmann, J., Emmerich, N.P., Bachor, O.A., Stevanovic, S.,
1999. SYFPEITHI: database for MHC ligands and peptide motifs.
Immunogenetics 50 (3–4), 213–219.
Roberts, A., Thomas, W.D., Guarner, J., Lamirande, E.W., Babcock, G.J.,
Greenough, T.C., Vogel, L., Hayes, N., Sullivan, J.L., Zaki, S., Subbarao, K.,
Ambrosino, D.M., 2006. Therapy with a severe acute respiratory syndrome-
associated coronavirus-neutralizing human monoclonal antibody reduces
disease severity and viral burden in golden Syrian hamsters. J. Infect. Dis.
193 (5), 685–692.
Singh, H., Raghava, G.P., 2001. ProPred: prediction of HLA-DR binding sites.
Bioinformatics 17 (12), 1236–1237.
Subbarao, K., McAuliffe, J., Vogel, L., Fahle, G., Fischer, S., Tatti, K., Packard,
M., Shieh, W.J., Zaki, S., Murphy, B., 2004. Prior infection and passive
transfer of neutralizing antibody prevent replication of severe acute
respiratory syndrome coronavirus in the respiratory tract of mice. J. Virol.
78 (7), 3572–3577.
Yang, L.T., Peng, H., Zhu, Z.L., Li, G., Huang, Z.T., Zhao, Z.X., Koup, R.
A., Bailer, R.T., Wu, C.Y., 2006. Long-lived effector/central memory T-
cell responses to severe acute respiratory syndrome coronavirus (SARS-
CoV) S antigen in recovered SARS patients. Clin. Immunol. 120 (2),
171–178.
